Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

67 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial.
Dieci MV, Guarneri V, Tosi A, Bisagni G, Musolino A, Spazzapan S, Moretti G, Vernaci GM, Griguolo G, Giarratano T, Urso L, Schiavi F, Pinato C, Magni G, Lo Mele M, De Salvo GL, Rosato A, Conte P. Dieci MV, et al. Among authors: spazzapan s. Clin Cancer Res. 2022 Jan 15;28(2):308-317. doi: 10.1158/1078-0432.CCR-21-2260. Epub 2021 Oct 19. Clin Cancer Res. 2022. PMID: 34667023 Free PMC article.
Therapeutic management of breast cancer in the elderly.
Spazzapan S, Crivellari D, Bedard P, Lombardi D, Miolo G, Scalone S, Veronesi A. Spazzapan S, et al. Expert Opin Pharmacother. 2011 Apr;12(6):945-60. doi: 10.1517/14656566.2011.540570. Epub 2011 Feb 16. Expert Opin Pharmacother. 2011. PMID: 21323593 Review.
Target therapy in elderly breast cancer patients.
Carli P, Turchet E, Quitadamo D, Spada A, Miolo G, Lamaj E, Spazzapan S, Di Lauro V, Dolcetti R, Veronesi A, Crivellari D. Carli P, et al. Among authors: spazzapan s. Crit Rev Oncol Hematol. 2012 Sep;83(3):422-31. doi: 10.1016/j.critrevonc.2011.12.004. Epub 2012 Jan 17. Crit Rev Oncol Hematol. 2012. PMID: 22257652 Review.
Anthracycline-free neoadjuvant therapy induces pathological complete responses by exploiting immune proficiency in HER2+ breast cancer patients.
Miolo G, Muraro E, Martorelli D, Lombardi D, Scalone S, Spazzapan S, Massarut S, Perin T, Viel E, Comaro E, Talamini R, Bidoli E, Turchet E, Crivellari D, Dolcetti R. Miolo G, et al. Among authors: spazzapan s. BMC Cancer. 2014 Dec 15;14:954. doi: 10.1186/1471-2407-14-954. BMC Cancer. 2014. PMID: 25512030 Free PMC article. Clinical Trial.
The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer.
Gori S, Inno A, Fiorio E, Foglietta J, Ferro A, Gulisano M, Pinotti G, Gubiotti M, Cavazzini MG, Turazza M, Duranti S, De Simone V, Iezzi L, Bisagni G, Spazzapan S, Cavanna L, Saggia C, Bria E, Cretella E, Vici P, Santini D, Fabi A, Garrone O, Frassoldati A, Amaducci L, Saracchini S, Evangelisti L, Barni S, Gamucci T, Mentuccia L, Laudadio L, Zoboli A, Marchetti F, Bogina G, Lunardi G, Boni L. Gori S, et al. Among authors: spazzapan s. PLoS One. 2015 Sep 4;10(9):e0136731. doi: 10.1371/journal.pone.0136731. eCollection 2015. PLoS One. 2015. PMID: 26340098 Free PMC article.
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, Láng I, Gómez HL, Tondini C, Ciruelos E, Burstein HJ, Bonnefoi HR, Bellet M, Martino S, Geyer CE Jr, Goetz MP, Stearns V, Pinotti G, Puglisi F, Spazzapan S, Climent MA, Pavesi L, Ruhstaller T, Davidson NE, Coleman R, Debled M, Buchholz S, Ingle JN, Winer EP, Maibach R, Rabaglio-Poretti M, Ruepp B, Di Leo A, Coates AS, Gelber RD, Goldhirsch A, Regan MM; SOFT and TEXT Investigators and the International Breast Cancer Study Group. Francis PA, et al. Among authors: spazzapan s. N Engl J Med. 2018 Jul 12;379(2):122-137. doi: 10.1056/NEJMoa1803164. Epub 2018 Jun 4. N Engl J Med. 2018. PMID: 29863451 Free PMC article. Clinical Trial.
Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial.
Ruhstaller T, Giobbie-Hurder A, Colleoni M, Jensen MB, Ejlertsen B, de Azambuja E, Neven P, Láng I, Jakobsen EH, Gladieff L, Bonnefoi H, Harvey VJ, Spazzapan S, Tondini C, Del Mastro L, Veyret C, Simoncini E, Gianni L, Rochlitz C, Kralidis E, Zaman K, Jassem J, Piccart-Gebhart M, Di Leo A, Gelber RD, Coates AS, Goldhirsch A, Thürlimann B, Regan MM; members of the BIG 1-98 Collaborative Group and the International Breast Cancer Study Group. Ruhstaller T, et al. Among authors: spazzapan s. J Clin Oncol. 2019 Jan 10;37(2):105-114. doi: 10.1200/JCO.18.00440. Epub 2018 Nov 26. J Clin Oncol. 2019. PMID: 30475668 Free PMC article. Clinical Trial.
Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.
André F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, Iwata H, Conte P, Mayer IA, Kaufman B, Yamashita T, Lu YS, Inoue K, Takahashi M, Pápai Z, Longin AS, Mills D, Wilke C, Hirawat S, Juric D; SOLAR-1 Study Group. André F, et al. N Engl J Med. 2019 May 16;380(20):1929-1940. doi: 10.1056/NEJMoa1813904. N Engl J Med. 2019. PMID: 31091374 Clinical Trial.
67 results